Heart Attack Therapeutic Drugs and Companies Pipeline Review H1 2015

DALLAS, April 10, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Heart Attack - Pipeline Review, H1 2015" to its store. The report provides an overview of the Heart Attack's therapeutic pipeline.

The report "Heart Attack - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Heart Attack, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

The most common form of heart problem, the heart attack, occurs when the regular flow of oxygen-rich blood is unable to pass through the heart at its regular pace. Under these circumstances immediate treatment needs to be done otherwise the heart muscles which are not receiving blood dies out. Heart attack is one of the rising concerns among people across the world. It's the leading killer in the US followed by some of the European countries and Japan. Forecasts have shown that the occurrences of heart attack are set to increase in the years to come. The causes of the attack can be either immutable or modifiable ie, it can be a cause of certain factors such as age, sex, heredity or factors that are manageable like diet, obesity, tobacco consumption, stress, and physical inactivity.

The markets for treatment of heart attacks are expected to grow at a CAGR of 1.6% from 2010 to 2016. Of the market players Pfizer is one of the leading companies to offer the best treatment, followed by Sanofi, AstraZeneca, Novartis, Merck and BMS. Some of the best medicines available in the market are Novartis's Diovan, Pfizer's Norvasc, Benicar and other offerings from Lipitor, Norvasc, Caduet, and Viagra. There is a constant effort by these leading companies and scientists to come up with even better ways of treatment. It has also aided the world by a drop in the number of death cases reported because of heart attacks. The market is full of opportunities so anyone with a knowledge of the industry and the right kind of drug can play a vital role.

The report on Heart Attack - Pipeline Review, H1 2015 gives a better understanding of the treatment being meted out in different regions by different institutions. The report includes details of 10 vital drugs for this attack. These are AB-002, APT-102, Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders, LA-8045, LWnt-3a, Lysimab, NVX-308, Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure, Small Molecule for Reperfusion Injury and Heart Attack and Small Molecules to Inhibit PDE5 for Cardiovascular Disease. This section of the report covers a description of the products, mechanism of action (MoA), R&D work done till date and other details related to profiling. Order a Purchase copy of this report @http://www.rnrmarketresearch.com/contacts/purchase?rname=314365  . (This is a premium report priced at US$2000 for a single user License.)

The report covers all the latest news and recent developments in the medication and therapeutic market. It has a list of projects that are dormant and reasons for the same. A person referring to this report will be able to analyse the market condition and understand the way forward. It helps one to build their strategies and counter-strategies to attain the competitive advantage in the market. It helps the reader to identify its competitor and gives a snapshot of the unexplored opportunities in the market. For newcomers and emerging players this information would be highly useful in order to plan its way ahead. The report assists its readers to create a proposal for in-licensing and out-licensing strategies, companies looking forward for merger and acquisition will also find this report very useful. To summarize we can say that report provides a detailed assessment of all pipeline projects ie for monotherapy as well as combination therapy. It provides a snapshot of the global therapeutic landscape of Heart Attack.

Global Markets Direct's report on Heart Attack has been compiled from personal databases of the Global Markets Direct, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Many other medical papers have been screened and the data extracted therein has been collated together as the report.

Explore more reports on Biotechnology at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com